BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  BIOSECURE Act

  US Manufacturing Unprepared for BIOSECURE Act’s Repercussions

  As the pharma industry awaits congressional action on the bill, gaping holes in the domestic drug manufacturing ecosystem have never been clearer.

  August 21, 2024

   · 

  5 min read

   · 

  Keerthi Vedantam
• 

  Podcast

  New IRA Drug Prices, Lots of Layoffs, Moderna’s Vaccine Opportunity

  Last week, the Biden administration revealed the first drug prices negotiated under the Inflation Reduction Act; Lykos, Grail and others make substantial staffing cuts, and Pfizer/BioNTech see mixed results for their COVID/flu vaccine.

  August 21, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Approvals

  FDA Denies Approval of Regeneron’s Linvoseltamab for Multiple Myeloma, Cites Third-Party Issues

  The regulator’s Complete Response Letter flagged problems at a third-party fill/finish site, which Regeneron says it has already addressed. The manufacturing facility is currently awaiting reinspection.

  August 21, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  GLP-1

  Novo’s Semaglutide Potentially Linked to Higher Risk of Suicidal Thoughts: Study

  Patients taking Novo Nordisk’s blockbuster GLP-1 drug appear to be more likely to harbor thoughts of suicide or self-harm, especially if they are already suffering from anxiety or depressive disorders, according to a new study.

  August 21, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  GLP-1

  As Novo and Lilly Focus on a Few Big Markets, Sanofi Seeks Global Reach for Diabetes GLP-1 Drug

  Experts say Novo Nordisk and Eli Lilly’s GLP-1 drugs are unlikely to reach more countries in the near term, but Sanofi’s diabetes treatment has gained ground globally.

  August 21, 2024

   · 

  5 min read

   · 

  Patience Asanga
• 

  Compensation

  Pay Range Transparency: New Law Could Help Massachusetts Biopharma Industry

  Massachusetts’ new salary range transparency law can be a tool for companies looking to attract biopharma professionals while also helping candidates and current employees improve their job searches and salaries, according to two experts.

  August 21, 2024

   · 

  5 min read

   · 

  Angela Gabriel
• 

  China

  House Lawmakers Raise Alarm About US Biopharma Companies Working With Chinese Military on Trials

  In a letter to FDA Commissioner Robert Califf, a House committee flagged several U.S. companies—including Eli Lilly and Pfizer—that have allegedly worked with the People’s Liberation Army on clinical trials in Xinjiang, raising ethical and intellectual property concerns.

  August 21, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Government

  Judge Blocks FTC Rule That Banned Most New Noncompete Clauses

  The federal judge’s decision Tuesday said the Federal Trade Commission exceeded its statutory authority in implementing a final rule aimed at restricting noncompete clauses.

  August 21, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Layoffs

  Aadi Bioscience to Lay Off 80% of R&D Staff

  Aadi Bioscience expects that pipeline adjustments and the workforce reduction will extend its cash runway into at least the second half of 2026.
  
  

  August 21, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• Press Releases

  Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer’s Association Award

  August 21, 2024

   · 

  7 min read